Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Neurorrhaphy Only vs Neurorrhaphy Plus PRF vs Neurorrhaphy Plus Nano-fat in Management of Traumatic Facial Nerve Injury

NCT06977607 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2024-10-01
Last updated
2025-05-18

Condition(s) studied

Facial Nerve InjuriesFacial Trauma

Investigational drug(s) / intervention(s)

Platelets Rich FibrinNano-fat stem cells (NFSCs)Repair only

Platelets Rich Fibrin: Repair of facial nerve injury plus Platelets Rich Fibrin will be injected around the repair and measure the out come in comparison with (Repair only) and (Repair Plus Nano-fat stem cells)

Nano-fat stem cells (NFSCs): Repair of facial nerve injury plus Nano fat derived stem cells will be injected around the repair and measure the out come in comparison with (Repair only) and (Repair Plus Platelets Rich Fibrin).

Repair only: facial nerve neurorrhaphy only (repair only) after acute facial nerve trauma and measure the out come in comparison with (Repair plus Nano- fat Stem Cells) and (Repair Plus Platelets Rich Fibrin).

Study summary

The current clinical trial aims to identify the most significant intervention that improves the outcome of post-traumatic facial nerve injury by comparing the following different modalities: neurorrhaphy alone, neurorrhaphy with PRF injection, and neurorrhaphy with Nanofat stem cells graft injection for significantly better Facial nerve regeneration.

Eligibility

Sex
ALL
Min age
20 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * Recent Facial nerve injury within the first 24 hours of trauma. * Grade V according to Sunderland classification. Exclusion Criteria: * Diabetes Mellitus. * Steroid Dependent.

Primary outcome measure(s)

  • Physical examination of the affected facial muscles after injury and Record the time taken for the first muscle excursion to occur following each facial nerve repair modality — 12 months
    \*\*Record the First Occurrence of Muscle Excursion and Movement by facial nerve Physical examination\*\* Based on monthly follow-up records Physical examination of the facial muscles affected after the nerve repair is done. Record the time taken for the first muscle excursion ( movement) to occur following each facial nerve repair modality. Comparing the time interval for each modality - the earlier the occurrence, the better the outcome.

Trial sites (1)

FacilityCityRegionStatus
Assiut University Asyut Asyut Governorate
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06977607 on ClinicalTrials.gov ↗ ← All trials in Egypt